High "population attributable fraction" for coronary heart disease mortality among relatives in monogenic familial hypercholesterolemia

Genetics in Medicine

Volumn 4, Issue 4, 2002, Pages 275-278

  Austin, Melissa A ^a,d   Zimmern, Ron L ^b   Humphries, Steve E ^c  

^a UNIVERSITY OF WASHINGTON   (United States)

^b UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^c ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

^d UNIVERSITY OF WASHINGTON   (United States)

Author keywords

Coronary heart disease; Hypercholesterolemia; Mortality; Population attributable fraction

Indexed keywords

CHOLESTEROL;

ARTICLE; CONTROLLED STUDY; FAMILIAL HYPERCHOLESTEROLEMIA; FEMALE; HIGH RISK POPULATION; HUMAN; INHERITANCE; ISCHEMIC HEART DISEASE; MALE; MONOGENIC DISORDER; MORTALITY; RISK FACTOR; ADULT; AGED; CORONARY ARTERY DISEASE; GENETICS; HYPERLIPOPROTEINEMIA TYPE 2; MIDDLE AGED; PUBLIC HEALTH;

ADULT; AGED; CORONARY DISEASE; FEMALE; HUMANS; HYPERLIPOPROTEINEMIA TYPE II; MALE; MIDDLE AGED; PUBLIC HEALTH; RISK FACTORS;

EID: 0036653039     PISSN: 10983600     EISSN: None     Source Type: Journal    
DOI: 10.1097/00125817-200207000-00005     Document Type: Article

References (32)

1. Goldstein JL, Hobbs HH, Brown MS. Familial hypercholesterolemia. In: Scriver CR, Beaudet AL, Sly WS, Valle D, editors. The metabolic basis of inherited disease. New York: McGraw Hill, 1995:1981-2030.
2. Scientific Steering Committee on behalf of the Simon Broome Register Group. Mortality in treated heterozygous familial hypercholesterolemia: implications for clinical management. Atherosclerosis 1999;142:105-112.
3. Simon Broome Steering Committee. Risk of fatal coronary heart disease in familial hypercholesterolemia. Scientific Steering Committee on behalf of the Simon Broome Register Group. BMJ 1991;303:893-896.
4. Neil HAW, Hammond T, Huxley R, Matthews DR, Humphries SE. Extent of underdiagnosis of familial hypercholesterolemia in routine practice: prospective registry study. BMJ 2000;321:148.
5. Day INM, Whittall RA, O'Dell SD, Haddad L, Bolla MK, Gudnason V, Humphries SE. Spectrum of LDL receptor gene mutations in heterozygous familial hypercholesterolemia. Hum Mutat 1997;10:116-127.
6. Heath KE, Humphries SE, Middleton-Price H, Boxer M. A molecular genetic service for diagnosing individuals with familial hypercholesterolaemia (FH). Eur J Hum Gen 2001;9:244-252.
7. Marks D, Wonderling D, Thorogood M, Lambert H, Humphries SE, Neil HAW. Screening for hypercholesterolaemia versus case finding for familial hypercholesterolaemia: a systematic review and cost-effectiveness analysis. Health Technol Assess 2000;4:1-123.
8. Umans-Eckenhausen MAW, Defesche JC, Sijbrands EJG, Scheerder RLMJ, Kastelein JJ. Review of the first 5 years of screening for familial hypercholesterolemia in the Netherlands. Lancet 2001;357:165-168.
9. Levin MS. The occurrence of lung cancer in man. Acta Unio Int Contra Cancrum 1953;9:531-541.
10. Hennekens CH, Buring JE. Attributable risk. In: Mayrent SL, Doll SR, editors. Epidemiology in medicine. Boston: Little, Brown and Company, 1987:87-95.
11. Khoury MJ, Beaty TH, Cohen BH. Attributable fraction. In: Fundamentals of genetic epidemiology. New York: Oxford University Press, 1993:77-79.
12. Krawczak M, Cooper DN, Schmidtke J. Estimating the efficacy and efficiency of cascade genetic screening. Am J Hum Genet 2001;69:361-370.
13. Shepherd J, Cobbe SM, Ford I, Isles CG, Lorimer AR, MacFarlane PW, McKillop JH, Packard CJ. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study. N Engl J Med 1995;333:1301-1307.
14. Smilde TJ, van Wissen S, Wollersheim H, Trip MD, Kastelein JJP, Stalenhoef AFH. Effect of aggressive versus conventional lipid lowering on atherosclerosis progression in familial hypercholesterolaemia (ASAP): a prospective, randomised, double-blind trial. Lancet 2001;357:577-581.
15. Corti R, Fayad ZA, Fuster V, Worthley SG, Helft G, Chesebro J, Mercuri M, Badimon JJ. Effects of lipid-lowering by simvastatin on human atherosclerotic lesions. A longitudinal study by high-resolution, noninvasive magnetic resonance imaging. Circulation 2001;104:249-252.
16. Anderson KM, Wilson PWF, Odell PM, Kannel WB. An updated coronary risk profile. A statement for health professionals. Circulation 1991;83:356-362.
17. Hingorani AD, Vallance P. A simple computer program for guiding management of cardiovascular risk factors and prescribing. BMJ 1999;318:101-105.
18. Bhatnagar D, Morgan J, Siddiq S, Mackness MI, Miller JP, Durrington PN. Outcome of case finding among relatives of patients with known heterozygouts familial hypercholesterolemia. BMJ 2000;321:1-5.
19. Wood D. Established and emerging cardiovascular risk factors. Am Heart J 2001; 141:549-557.
20. Executive summary of the third report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 2001;285:2486-2497.
21. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994;344:1383-1389.
22. Familial hypercholesterolemia. Report of a second WHO consultation in Geneva. World Health Organization, Human Genetics Program, Geneva, October, 1999.
23. Tonstad S. Familial hypercholerolaemia: a pilot study of parents and childrens' concerns. Acta Pediatr 1996;85:1307-1313.
24. Tonstad S, Novik TS, Vandvik IH. Psychosocial function during treatment for familial hypercholesterolaemia. Pediatrics 1996;98:249-255.
25. Rosenthal SL, Knauer-Black S, Stahl MP, Catalanotto TJ, Sprecher DL. The psychological functioning of children with hypercholesterolemia and their families. Clin Pediatr (Phila) 1993;32:135-141.
26. Humphries SE, Galton D, Nicholls P. Genetic testing for familial hypercholesterolaemia: practical and ethical issues. Q J Med 1997;90:169-181.
27. Haq IU, Ramsay LE, Yeo WW, Jackson PR, Wallis EJ. Is the Framingham risk function valid for northern European populations? A comparison of methods for estimating absolute coronary risk in high risk men. Heart 1999;81:40-46.
28. D'Agostino RBS, Grundy S, Sullivan LM, Wilson P, for the CHD Risk Prediction Group. Validation of the Framingham coronary heart disease prediction score. Results of a multiple ethic groups investigation. JAMA 2001;286:180-187.
29. Tybjaerg-Hansen A, Steffensen R, Meinertz H, Schnohr P, Nordestgaard BG. Association of mutations in the apolipoprotein B gene with hypercholesterolemia and the risk of ischemic heart disease. N Engl J Med 1998;338:1577-1584.
30. Garcia CK, Wilund K, Area M, Zuliani G, Fellin R, Maioli M, Calandra S, Bertolini S, Cossu F, Grishin N, Barnes R, Cohen JC, Hobbs HH. Autosomal recessive hypercholesterolemia caused by mutations in a putative LDL receptor adaptor protein. Science 2001;292:1394-1398.
31. Thompson GR. What targets should lipid-modulating therapy achieve to optimise the prevention of coronary heart disease? Atherosclerosis 1997;131:1-5.
32. Freeman DJ, Norrie J, Sattar N, Neely RD, Cobbe SM, Ford I, Isles C, Lorimer AR, Macfarlane PW, McKillop JH, Packard CJ, Shepherd J, Gaw A. Pravastatin and the development of diabetes mellitus: evidence for a protective treatment effect in the West of Scotland Coronary Prevention Study. Circulation 2001;103:357-362.